WI-SHINE-MEDICAL
SHINE Medical Technologies LLC and Von Gahlen International Inc. today announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis.
The supercell will house the key processes at the end of isotope production, including the extraction, purification and packaging of the molybdenum-99, or Mo-99, produced elsewhere in the plant. The hot cells allow for remote operation of the process equipment using specialized features, designed through close collaboration between SHINE and Von Gahlen engineers.
Von Gahlen has its headquarters in the Netherlands and is a state-of-the-art manufacturer of shielding solutions for nuclear medicine and radiopharmacy. Von Gahlen was awarded the contract for the supercell based on this expertise, commitment to the project, and its alignment with SHINE’s core values. Fabrication of the hot cells is underway and delivery is expected in the second half of 2021.
“We’re excited to be working with such an experienced hot cell manufacturer as our partner on such an important part of our production facility,” said Greg Piefer, founder and CEO of SHINE. “Von Gahlen is a strong addition to the high-quality team that will deliver the largest Mo-99 production facility in the world, and, in doing so, ensure a long-term, reliable supply of medical isotopes, including Mo-99.”
SHINE’s isotope production facility will be capable of fulfilling two-thirds of the U.S. patient need for Mo-99. The isotope is relied on for 40 million patient procedures around the world each year, including heart disease and cancer diagnoses.
“The opportunity to help build SHINE’s one-of-a-kind U.S. plant is an honor that we have taken seriously throughout the process,” said Jaap Duiker, managing director of Von Gahlen. “We know our work must be exacting and precise. Through careful planning, close ongoing collaboration and years of experience, we look forward to fulfilling the critical needs required to deliver a superior product to SHINE.”
About SHINE Medical Technologies
SHINE is a nuclear technology company committed to improving the lives of patients around the world. The company is focused initially on the commercialization of medical isotopes, including molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer and other diseases, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcomes for some cancer patients. SHINE has created isotope production processes that will deliver products to benefit physicians and patients and help solve critical supply problems in the United States and markets in Europe and around the world. SHINE has a long-term strategy to solve some of humanity’s biggest problems and advance our vision for progressively broad and impactful uses of nuclear technology. For more information, please visit our website at www.shinemed.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123006188/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
Aptiv Powers Intelligent Edge Applications From Automotive to Robotics at CES 20265.1.2026 07:01:00 CET | Press release
Showcase Features Aptiv Technologies Enabling Intelligent Cars, Commercial Vehicles, Robots, and Other Mission Critical ApplicationsImmersive Demos Highlight End-to-End AI for Autonomy, Personalized User Experience and Extensive Connectivity Aptiv PLC (NYSE: APTV),a global industrial technology company, will showcase at CES 2026 how its intelligent edge solutions enable devices to sense, think, and act in real time—while continuously optimizing performance throughout their lifecycle. This approach brings advanced computing and artificial intelligence closer to where data is generated, unlocking AI-driven solutions for transportation, robotics, aerospace, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104888341/en/ Aptiv Powers the Intelligent Edge from Automotive to Robotics at CES 2026 By processing data locally at the edge, rather than relying solely on centralized cloud systems, Aptiv’s solutions enable fas
Belkin styrker beskyttelsen af hverdagsenheder med en ny serie skærmbeskyttere og et Wear & Tear-program4.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer syv nye skærmbeskyttere, der er udviklet med proprietær Nano-Titan-teknologi for øget styrke mod daglige fald og ridser Et Wear and Tear-program skaber ro i sindet for forbrugere, der ønsker at udskifte deres produkter Forbrugerne kan nu personalisere deres skærmbeskyttere med Screen Skinz Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerer i dag en ny klasse af løsninger til skærmbeskyttelse, et strategisk partnerskab og et helt nyt wear-and-tear-program, der styrker virksomhedens engagement i at beskytte enheder og give forbrugerne tryghed. Lanceringen omfatter syv nye skærmbeskyttere, et partnerskab med ScreenSkinz vedrørende personalisering, og et program til udskiftning af skærmbeskyttere beregnet til at give brugerne varig ro i sindet og sikre, at de produkter, de elsker, forbliver trygge, sikre og i den bedste form. Mød ScreenForce Titan-serien: Det ultimative inden for fuldskærmsbeskyttelse Titan SmartShield Titan SmartShield fungerer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom